trending Market Intelligence /marketintelligence/en/news-insights/trending/-BBp4O2m8QBJgl0G--6a7g2 content esgSubNav
In This List

Aeterna Zentaris shareholder lawsuit on drug Macrilen gets class certification

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Aeterna Zentaris shareholder lawsuit on drug Macrilen gets class certification

Aeterna Zentaris Inc. said a shareholder lawsuit against the company regarding its hormone deficiency drug Macrilen received class certification.

The U.S. District Court for the District of New Jersey granted class certification to the lawsuit, filed against the company and certain of its current and former officers. The shareholders sued the company for allegedly making false statements regarding the safety and efficacy of Macrilen and its prospects for approval by the U.S. Food and Drug Administration.

The FDA rejected the new drug application for Macrilen, also known as macimorelin, in 2014, and Aeterna resubmitted the application in July 2017. In December 2017, the regulator approved the drug for use in the diagnosis of adult growth hormone deficiency.

The Summerville, S.C.-based company said it intends to defend the lawsuit and believes that substantially all costs for its defense will be covered by insurers. The company also said that since it cannot predict the suit's outcome or estimate any possible loss, it has not recorded any liability related to the lawsuit.